ALLO-329
Autoimmune Disease
Phase 1Active - RESOLUTION trial now enrolling
Key Facts
Indication
Autoimmune Disease
Phase
Phase 1
Status
Active - RESOLUTION trial now enrolling
Company
About Allogene Therapeutics
Allogene Therapeutics is dedicated to creating and leading the next revolution in cell therapy by delivering the first allogeneic CAR T cell products. The company leverages its proprietary AlloCAR T platform, featuring multiplex gene-engineering, gene-editing, and a proprietary lymphodepletion regimen, to develop scalable, on-demand treatments. With a pipeline targeting blood cancers, solid tumors like renal cell carcinoma, and autoimmune diseases, Allogene is advancing multiple clinical programs, including the industry's first pivotal Phase 2 trial for a frontline allogeneic CAR T in lymphoma. The company is publicly traded and led by a team with deep CAR T expertise.
View full company profileTherapeutic Areas
Other Autoimmune Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| ZB021 | Zenas BioPharma | Not Disclosed |
| ZB022 | Zenas BioPharma | Not Disclosed |
| Plonmarlimab | Xencor | Clinical |
| ATA3219 | Atara Biotherapeutics | Preclinical |